Similar articles

• Potentiating effects of combined usage of three sulfonylurea drugs on the occurrence of alloxan diabetes in rats.

  Katsumata K, Katsumata Y, Ozawa T, Katsumata K Jr. Katsumata K, et al. Horm Metab Res. 1993 Feb;25(2):125-6. doi: 10.1055/s-2007-1002058. Horm Metab Res. 1993. PMID: 8458609 No abstract available.
• [The influence of insulin on hyperlactacidemia in the course of alloxan diabetes and experimental dysthyroidism].

  Colev V, Sneer A, Dughir E, Papp E. Colev V, et al. Rev Med Chir Soc Med Nat Iasi. 1976 Oct-Dec;80(4):587-92. Rev Med Chir Soc Med Nat Iasi. 1976. PMID: 16296545 Romanian. No abstract available.
• Antidiabetic effects of S-methylcysteine sulphoxide on alloxan diabetes.

  Kumari K, Augusti KT. Kumari K, et al. Planta Med. 1995 Feb;61(1):72-4. doi: 10.1055/s-2006-958004. Planta Med. 1995. PMID: 7700997 No abstract available.
• Update on systemic management of diabetes.

  Masharani U, Rushakoff RJ. Masharani U, et al. Int Ophthalmol Clin. 2009 Spring;49(2):13-33. doi: 10.1097/IIO.0b013e31819fd36b. Int Ophthalmol Clin. 2009. PMID: 19349784 Review. No abstract available.
• Management of gestational diabetes: pharmacologic treatment options and glycemic control.

  Langer O. Langer O. Endocrinol Metab Clin North Am. 2006 Mar;35(1):53-78, vi. doi: 10.1016/j.ecl.2005.09.007. Endocrinol Metab Clin North Am. 2006. PMID: 16310642 Review. No abstract available.